Immutep Limited American Depositary Shares - IMMP STOCK NEWS

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced an expansion of Part B in its TACTI-002 Phase II trial for second line Non-Small Cell Lung Cancer (NSCLC), following a positive safety and efficacy review. The study, conducted in collaboration with Merck & Co., aims to evaluate the combination of efti and KEYTRUDA® in multiple cancer types. Additional patient recruitment will include 13 more NSCLC patients in Stage 2 of Part B. This trial represents an opportunity to advance treatment options in oncology and reflects Immutep's commitment to immunotherapy development.

Immutep Limited has announced that its interim Overall Survival results from the Phase IIb AIPAC study will be presented at the San Antonio Breast Cancer Symposium 2020, scheduled for December 11. The AIPAC trial evaluates the combination of eftilagimod alpha and paclitaxel in HR-positive metastatic breast cancer patients. This presentation is a significant opportunity to showcase research at an esteemed international conference attended by over 90 countries. The poster will be available on Immutep's website post-event.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced new interim results from its Phase II TACTI-002 study, presented on September 17, 2020. The trial investigates the combination of eftilagimod alpha and KEYTRUDA in patients with resistant head and neck squamous cell carcinoma and non-small cell lung cancer. Significant findings include three complete responses and an improved median progression-free survival (PFS) of 4.3 months in HNSCC and 11.8 months in NSCLC. The trial continues enrollment, with 89 out of 109 participants recruited by the cut-off date of August 21, 2020.

Immutep Limited (NASDAQ: IMMP) announced interim results from its INSIGHT-004 Phase I clinical trial, presented at ESMO Virtual Congress 2020. The trial evaluated the combination therapy of eftilagimod alpha and avelumab, showing a 41.7% partial response rate in 12 patients, an increase from 33% in previous assessments. The treatment demonstrated promising activity in cancers typically resistant to immune checkpoint inhibitors. Importantly, the therapy was found to be safe and well-tolerated, with no dose-limiting toxicities.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has received a A$671,427 grant from the Australian Research Council to continue its research collaboration with Monash University focused on Lymphocyte Activation Gene-3 (LAG-3). This funding, awarded under the ARC’s Linkage Project scheme, will support ongoing studies into LAG-3's structure and its impact on T cell function over the next three years. The collaboration, which began in 2017, aims to uncover insights that may lead to innovative treatments for cancer and autoimmune diseases.

Immutep has successfully enrolled 23 patients for Stage 1, Part B of its TACTI-002 Phase II study, focusing on second-line Non-Small Cell Lung Cancer (NSCLC). With 87 out of a target of 109 patients (80%) enrolled, recruitment for Stage 2 of Part C continues. The trial, partnered with Merck & Co., evaluates the combination of Immutep's eftilagimod alpha with KEYTRUDA in patients with head and neck squamous cell carcinoma and NSCLC. Further safety and efficacy data will be reviewed by a Data Monitoring Committee before proceeding with additional recruitment.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has been granted a new United States patent for its LAG525 antibody, which is a humanised form of its IMP701 antibody. This patent covers essential components for producing LAG525, and it will expire on March 26, 2035. LAG525 is currently being evaluated in five clinical trials, in combination with Novartis’ PD1 inhibitor, spartalizumab, for cancer treatment. The company is eligible for milestone payments and royalties after commercialization. This development strengthens Immutep's position in the biopharmaceutical sector.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced a cash rebate of A$1,437,826 from the Australian Federal Government’s R&D tax incentive program. This rebate pertains to eligible R&D activities conducted in the fiscal year 2019, particularly related to the TACTI-mel and TACTI-002 clinical trials of its lead compound, eftilagimod alpha. Immutep's approved Advance Finding allows for extended eligibility for tax incentives for its R&D efforts until June 30, 2021. The funding will be directed towards ongoing clinical trials.

Immutep announces a cash payment of €2,173,454 (~US$2,407,817) from the French Government under the Crédit d’Impôt Recherche tax incentive scheme. This program reimburses 30% of eligible R&D expenditures for French companies involved in research. Immutep qualifies through its subsidiary for R&D activities conducted in France. The funds will be allocated to support the global clinical development of eftilagimod alpha and the preclinical development of IMP761.